A combination of dabrafenib and trametinib demonstrated promising efficacy in patients with rare gastrointestinal cancers linked to a mutation of the BRAF gene, according to research presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

Zev Wainberg, MD, of the department of medicine at UCLA, and colleagues explored the drug combination’s efficacy among patients with biliary tract cancer (BTC) and adenocarcinoma of the small intestine (ASI) who had previously received treatment with at least one line of systemic therapy. The median progression-free survival in both cancers is less than 5 months.